Company intelligence / Profile preview

Jiangsu Jiarui Biotechnology

Jiangsu, China

Ownership: Private
Development stage: Other

Overview

The company's lead drug candidate, JR8603, is in a Phase 1 clinical trial evaluating its safety, tolerability, and preliminary efficacy in patients with advanced malignant solid tumors. The trial includes dose escalation and expansion stages, with endpoints such as safety, maximum tolerated dose, pharmacokinetics, and biomarker analysis, including serum Legumain levels. No efficacy or safety outcomes beyond initiation and endpoints have been published as of the last update.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

JR8603

1 more asset in the full pipeline.

Request access →

Partnerships

JiaRay Therapeutics

Beyond the preview

Go deeper on Jiangsu Jiarui Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Jiarui Biotechnology.

Explore the full profile